Technical Analysis for PFNX - Pfenex Inc.

Grade Last Price % Change Price Change
grade B 9.25 3.93% 0.35
PFNX closed up 3.93 percent on Friday, October 18, 2019, on approximately normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Earnings due: Nov 5

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Up
See historical PFNX trend table...

Date Alert Name Type % Chg
Stochastic Reached Overbought Strength 0.00%
Overbought Stochastic Strength 0.00%
NR7 Range Contraction 6.57%
20 DMA Support Bullish 4.28%
MACD Bullish Signal Line Cross Bullish 4.28%
Calm After Storm Range Contraction 4.28%
Stochastic Reached Overbought Strength 4.28%
Overbought Stochastic Strength 4.28%
Calm After Storm Range Contraction 3.24%
NR7 Range Contraction 3.24%

Older signals for PFNX ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Pfenex Inc., a clinical-stage biotechnology company, is engaged in the development of biosimilar therapeutics. Its lead product candidate includes PF582, a biosimilar candidate to Lucentis that is in Phase Ib/IIa trials in patients with wet age-related macular degeneration. The company also develops PF530, an interferon beta-1b biosimilar candidate to the Betaseron to reduce the relapses in patients with relapsing forms of multiple sclerosis; PF694, an interferon alpha-2a biosimilar candidate to the reference product Pegasys; and other biosimilar candidates. In addition, it develops PF708, a teriparatide generic peptide product candidate to the reference listed drug Forteo; Px563L, an anthrax vaccine candidate based on a recombinant modified form of the protective antigen; and Px533, a prophylactic vaccine candidate to protect against malaria infection. The company has collaboration with Strides Arcolab Limited for the development of PF530. Pfenex Inc. is headquartered in San Diego, California.
Medicine Biotechnology Life Sciences Biology Drugs Multiple Sclerosis Wet Age Related Macular Degeneration Biosimilar Anthrax Antivirals Interferon
Is PFNX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 10.2
52 Week Low 3.13
Average Volume 368,758
200-Day Moving Average 6.2297
50-Day Moving Average 8.1466
20-Day Moving Average 8.559
10-Day Moving Average 8.794
Average True Range 0.5924
ADX 16.49
+DI 24.6238
-DI 17.4632
Chandelier Exit (Long, 3 ATRs ) 8.2528
Chandelier Exit (Short, 3 ATRs ) 8.7372
Upper Bollinger Band 9.4625
Lower Bollinger Band 7.6555
Percent B (%b) 0.88
BandWidth 21.112279
MACD Line 0.194
MACD Signal Line 0.1592
MACD Histogram 0.0348
Fundamentals Value
Market Cap 217.62 Million
Num Shares 23.5 Million
EPS 0.06
Price-to-Earnings (P/E) Ratio 154.17
Price-to-Sales 1.08
Price-to-Book 1.09
PEG Ratio -0.03
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 10.32
Resistance 3 (R3) 10.26 9.84 10.14
Resistance 2 (R2) 9.84 9.56 9.87 10.08
Resistance 1 (R1) 9.54 9.39 9.69 9.61 10.02
Pivot Point 9.12 9.12 9.20 9.15 9.12
Support 1 (S1) 8.83 8.85 8.98 8.89 8.48
Support 2 (S2) 8.41 8.68 8.44 8.42
Support 3 (S3) 8.11 8.41 8.36
Support 4 (S4) 8.18